arrow
T

Tetsuo Takehara

osaka university
H指数:74
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All-Cause Mortality After SVR in Advanced Chronic Hepatitis C

血清缺乳糖基 IgG 预测晚期慢性丙型肝炎患者实现 SVR 后的肝细胞癌及全因死亡率

2026-09-070
OAAI
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

代谢功能障碍相关脂肪性肝病(MASLD)2026年循证临床实践指南

2026-05-120
OAAI
On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years

核苷(酸)类似物治疗>10年的患者中,治疗期间病毒因素影响后续乙型肝炎表面抗原血清清除

2026-04-210
OA
Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

抗凝治疗反应对肝硬化合并门静脉血栓患者肝脏相关事件的影响

2026-03-010
OAAI
LSECs promote MASH progression via IL-1R1-mediated chemokine production induced by macrophage-derived IL-1β

肝窦内皮细胞(LSECs)通过巨噬细胞来源的IL-1β诱导的IL-1R1介导的趋化因子产生促进MASH进展。

2025-12-020
OAAI
Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial

直接抗病毒药物治疗后,丙型肝炎病毒相关失代偿性肝硬化患者肝脏储备功能和预后的长期变化:一项日本III期试验的五年随访研究

2025-10-300
PRE
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma

不可切除肝细胞癌中,阿替利珠单抗联合贝伐珠单抗后使用乐伐替尼与乐伐替尼作为一线治疗的比较分析

2025-10-250
PRE
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study

长链非编码RNA PWRN4与术后SVR相关肝细胞癌:一项全基因组关联研究

2025-09-260
OAAI
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

血清生长分化因子15可作为预测丙型肝炎病毒肝硬化患者病毒清除后预后的新型生物标志物

2025-09-180
OAAI
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

高血压作为潜在影响不可切除肝细胞癌患者阿替利珠单抗联合贝伐珠单抗治疗疗效的不良事件

2025-09-011
OAAI
Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy

治疗后血清CXCL10水平可对慢性丙型肝炎病毒感染导致的代偿期和失代偿期肝硬化患者的生存情况进行分层,尤其是在直接抗病毒治疗后。

2025-07-010
PRE
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis

治疗前血清血管生成素-2可预测接受索磷布韦和韦帕他韦成功清除HCV后,HCV相关失代偿期肝硬化患者的预后及肝脏功能储备

2025-06-200
PRE
Single-cell analysis reveals immune cell abnormalities underlying the clinical heterogeneity of patients with systemic sclerosis

Shimagami, H.; Nishimura, K.; Matsushita, H.; Metsugi, S.; Kato, Y.; Kawasaki, T.; Tsujimoto, K.; Edahiro, R.; Itotagawa, E.; Naito, M.; et al. 单细胞分析揭示了系统性硬化症患者临床异质性的免疫细胞异常。Nat. Commun. 2025, 16, 4949. [Google Scholar] [CrossRef]

2025-06-170
OAAI
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
2025-03-110
OAAI